NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CMMB

Chemomab Therapeutics Ltd ADR

Jul 03 • 04:00PM ET

1.16

Dollar change +0.01
Percentage change 0.87	%

Healthcare • Biotechnology • Israel • NASD

Peers: VRTX ONC MDGL NBIX AKRO MNOV ARDX TXMD ETNB PBYI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	8.80%	Shs Outstand	18.86M	Perf Week	-2.82%
Market Cap	21.88M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	0.00%	Shs Float	17.20M	Perf Month	-13.43%
Enterprise Value	11.47M	PEG	-	EPS next Q	-0.07	Inst Own	10.58%	Short Float	0.91%	Perf Quarter	2.65%
Income	-13.40M	P/S	-	EPS this Y	-609.30%	Inst Trans	-48.94%	Short Ratio	1.12	Perf Half Y	-42.57%
Sales	0.00M	P/B	2.11	EPS next Y	-21.31%	ROA	-86.96%	Short Interest	0.16M	Perf YTD	-35.91%
Book/sh	0.55	P/C	2.04	EPS next 5Y	-	ROE	-112.99%	52W High	2.55 -54.51%	Perf Year	20.08%
Cash/sh	0.57	P/FCF	-	EPS past 3/5Y	13.38% 45.20%	ROIC	-126.78%	52W Low	0.87 33.33%	Perf 3Y	-71.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.34% 5.26%	Perf 5Y	-95.10%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	52.66%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.39	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.33	EPS Q/Q	47.38%	SMA20	-4.56%	Beta	0.52	Target Price	8.50
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-9.21%	Rel Volume	0.28	Prev Close	1.15
Employees	16	LT Debt/Eq	0.02	Earnings	May 15 BMO	SMA200	-23.80%	Avg Volume	140.58K	Price	1.16
IPO	Feb 12, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	92.63% -	Trades		Volume	39,709	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-24	Initiated	Maxim Group	Buy	$4
May-06-24	Upgrade	Oppenheimer	Perform → Outperform	$6
Dec-19-23	Resumed	ROTH MKM	Buy	$7

Jun-30-25 08:00AM	Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 (GlobeNewswire)
Jun-11-25 08:00AM	Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis (GlobeNewswire) -7.48%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-03-25 08:00AM	Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis (GlobeNewswire)
10:53AM	Loading…
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks)
May-29-25 10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
May-15-25 08:00AM	Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.61%
May-05-25 08:00AM	Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 (GlobeNewswire) -6.34%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Apr-28-25 08:00AM	Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases (GlobeNewswire)
Apr-21-25 08:00AM	Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences (GlobeNewswire)
08:00AM	Loading…
Apr-15-25 08:00AM	Chemomab Announces New Medical and Clinical Appointments (GlobeNewswire)
Mar-27-25 08:30AM	Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers (GlobeNewswire) -5.17%
Mar-06-25 08:00AM	New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis (GlobeNewswire) +5.71%
Mar-03-25 08:00AM	Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) -10.12%
Feb-19-25 07:00AM	Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis (GlobeNewswire)
Feb-03-25 07:00AM	Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-03-24 07:00AM	Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit (GlobeNewswire)
Nov-19-24 07:00AM	Oral Presentation at AASLD The Liver Meeting 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis (GlobeNewswire)
Nov-14-24 07:00AM	Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-30-24 07:00AM	Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire)
Oct-15-24 07:00AM	Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting 2024 (GlobeNewswire) +9.17%
Oct-01-24 07:00AM	Chemomab Therapeutics to Present at October 2024 Investor Conferences (GlobeNewswire)
Aug-28-24 07:00AM	Chemomab Therapeutics to Present at September 2024 Investor Conferences (GlobeNewswire) +12.73%
Aug-21-24 07:00AM	Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-12-24 07:00AM	Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire)
09:00AM	Loading…
Jul-30-24 09:00AM	Chemomab Therapeutics Announces Closing of $10 Million Private Placement (GlobeNewswire)
Jul-26-24 07:00AM	Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +6.72%
Jul-25-24 07:38AM	Chemomab Therapeutics Announces $10 Million Private Placement (GlobeNewswire) -16.20%
07:00AM	Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis (GlobeNewswire)
Jun-27-24 12:00PM	Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-18-24 07:00AM	Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis (GlobeNewswire) +11.54%
Jun-06-24 07:00AM	Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference (GlobeNewswire) -11.64%
May-17-24 07:00AM	Chemomab Therapeutics to Participate in Upcoming Scientific Conferences (GlobeNewswire)
May-10-24 09:55AM	Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-09-24 11:57AM	CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024 (InvestorPlace) +11.72%
07:00AM	Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:00AM	Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire) -18.42%
May-02-24 07:00AM	Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference (GlobeNewswire)
Apr-24-24 07:00AM	Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update (GlobeNewswire)
Apr-18-24 07:00AM	Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis (GlobeNewswire) +18.64%
Apr-02-24 07:00AM	Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 (GlobeNewswire)
Mar-25-24 07:06AM	Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis (GlobeNewswire) -5.60%
Mar-07-24 12:53PM	CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.63%
07:00AM	Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-05-24 07:00AM	Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference (PR Newswire)
Feb-20-24 07:00AM	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases (PR Newswire) +6.37%
Feb-14-24 07:00AM	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update (PR Newswire)
Feb-05-24 07:00AM	Chemomab Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +6.56%
Jan-30-24 07:00AM	Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis (PR Newswire) +7.41%
Jan-03-24 07:00AM	Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 (PR Newswire)
Nov-16-23 07:00AM	Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis (PR Newswire) -19.22%
Nov-15-23 07:00AM	Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis (PR Newswire) +33.93%
Nov-13-23 08:00AM	Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting 2023 (PR Newswire) -6.78%
Nov-09-23 08:00AM	Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire) -6.10%
Nov-06-23 04:15PM	Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement (PR Newswire) -6.78% -6.21%
Oct-30-23 07:00AM	Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update (PR Newswire) -7.15%
Oct-26-23 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Sep-28-23 07:00AM	Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference (PR Newswire)
Aug-29-23 07:00AM	Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 08:00AM	Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Jun-28-23 07:00AM	Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis (PR Newswire) -5.37%
Jun-26-23 07:00AM	Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 (PR Newswire) +28.00%
Jun-21-23 07:00AM	Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 (PR Newswire) -13.22%
Jun-05-23 07:00AM	Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update (PR Newswire)
Jun-02-23 09:00AM	Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis (PR Newswire) +8.12%
May-24-23 07:00AM	Chemomab Therapeutics to Participate in Upcoming Scientific Conferences (PR Newswire)
May-11-23 06:00AM	Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Apr-26-23 07:00AM	Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference (PR Newswire)
Apr-19-23 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Apr-12-23 07:00AM	Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Mar-29-23 08:30AM	Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023 (PR Newswire)
Mar-17-23 07:00AM	Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update (PR Newswire)
Mar-06-23 07:00AM	Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Feb-21-23 07:00AM	Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis (PR Newswire) +16.84%
Jan-03-23 07:00AM	Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients (PR Newswire) -8.13%
Dec-21-22 07:00AM	Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PR Newswire)
Nov-30-22 07:00AM	Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy (PR Newswire)
Nov-11-22 06:00AM	Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-09-22 08:00AM	Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 (PR Newswire)
Nov-01-22 07:00AM	Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Oct-28-22 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Aug-12-22 06:00AM	Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
06:00AM	Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities (PR Newswire)
Aug-01-22 07:00AM	Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Jun-27-22 08:00AM	Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis (PR Newswire)
Jun-21-22 07:00AM	Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors (PR Newswire) +5.42%
Jun-09-22 09:00AM	Chemomab Therapeutics to Present at June Investor and Scientific Conferences (PR Newswire)
Jun-02-22 07:00AM	Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022 (PR Newswire)
May-18-22 07:00AM	Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 06:00AM	Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-04-22 07:00AM	Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Mar-23-22 07:00AM	Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit (PR Newswire)
Mar-14-22 08:00AM	Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis (PR Newswire) -5.48%
Mar-09-22 06:00AM	Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-02-22 08:00AM	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update (PR Newswire)

Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OrbiMed Israel Partners Limite	Owner	Sep 12 '24	Proposed Sale	2.03	500,000	1,015,000		Sep 12 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMMB

Chemomab Therapeutics Ltd ADR

Upgrade your FINVIZ experience